Stay updated on Oral Azacitidine with Pembrolizumab in Metastatic Melanoma Clinical Trial
Sign up to get notified when there's something new on the Oral Azacitidine with Pembrolizumab in Metastatic Melanoma Clinical Trial page.

Latest updates to the Oral Azacitidine with Pembrolizumab in Metastatic Melanoma Clinical Trial page
- Check5 days agoChange DetectedAdded a government funding lapse notice affecting site updates and a page revision note showing version v3.4.1, replacing the previous v3.4.0.SummaryDifference0.4%

- Check12 days agoChange DetectedAdded Show glossary option and a display of Last Update Submitted that Met QC Criteria, along with a Revision: v3.4.0 and a No FEAR Act Data entry. Removed Last Update Submitted that met QC Criteria, No FEAR Act data, and the older Revision: v3.3.4.SummaryDifference0.2%

- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedA minor revision update from v3.3.3 to v3.3.4 is shown; there are no apparent changes to the study details, eligibility criteria, or other content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check47 days agoChange DetectedAdded a Locations section with Texas as the study site. The page revision updated to v3.3.3.SummaryDifference0.2%

- Check76 days agoChange DetectedRevision: v3.3.2 has been added and Revision: v3.2.0 has been removed, a minor metadata update to the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check83 days agoChange DetectedThe funding-status notice banner was removed. The page previously warned that information may be out of date due to a lapse in government funding.SummaryDifference0.4%

Stay in the know with updates to Oral Azacitidine with Pembrolizumab in Metastatic Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Oral Azacitidine with Pembrolizumab in Metastatic Melanoma Clinical Trial page.